External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 584-589

  Loeb, Stacy ^a   Carvalhal, Gustavo F ^b   Kan, Donghui ^b   Desai, Angel ^b   Catalona, William J ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biochemical recurrence; CAPRA; Prostate cancer; Prostatectomy; Staging

Indexed keywords

ARTICLE; CANCER OF THE PROSTATE RISK ASSESSMENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION STUDY;

DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84866760398     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.06.007     Document Type: Article

References (20)

1. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy vs. watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. Ca Cancer J Clin 2008, 58:71-96.
3. Albertsen P.C., Hanley J.A., Fine J. Twenty-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
4. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:110-114.
5. Shariat S.F., Karakiewicz P.I., Margulis V., et al. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008, 18:279-296.
6. Eastham J.A., Scardino P.T., Kattan M.W. Predicting an optimal outcome after radical prostatectomy: The Trifecta nomogram. J Urol 2008, 179:2207-2211.
7. Kattan M.W., Cuzick C.K., Fisher G., et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008, 112:69-74.
8. Kattan M.W., Eastham J.A., Stapleton A.M.F., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
9. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58:843-848.
10. Shariat S.F., Karakiewicz P.I., Suardi N., et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res 2008, 14:4400-4407.
11. Cooperberg M.R., Pasta D.J., Elkin E.P., et al. The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005, 173:1938-1942.
12. Cooperberg M.R., Broering J.M., Carroll P.R. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009, 101:878-887.
13. Cooperberg M.R., Freedland S.J., Pasta D.J., et al. Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006, 107:2384-2391.
14. May M., Knoll N., Siegsmund M., et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007, 178:1957-1962.
15. Zhao K.H., Hernandez D.J., Han M., et al. External validation of University of California, San Francisco, cancer of the prostate risk assessment score. Urology 2008, 72:396-400.
16. Kundu S.D., Roehl K.A., Eggener S.E., et al. Potency, continence, and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004, 172:2227-2231.
17. Suardi N., Porter C.R., Reuther A.M., et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008, 112:1254-1263.
18. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:269-274.
19. Mitchell J.A., Cooperberg M.R., Elkin E.P., et al. Ability of two pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. J Urol 2005, 173:1126-1131.
20. Greene K.L., Meng M.V., Elkin E.P., et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from Cancer of the Prostate Strategic Urological Research Endeavour (CaPSURE). J Urol 2004, 171:2255-2259.